2026 Hospice Valuation Multiples Report (US Market)
Audience: This report is written for hospice agency owners evaluating a sale and health care buyers evaluating acquisitions. It focuses on EBITDA multiples, with a short explanation of how revenue ties into valuation. Quick links: Hospice M&A | Home Health M&A | How to Value Your Healthcare Business | How to Sell a Hospice or Home Health Agency | Join Our Buyer NetworkKey takeaway: In 2026, strong agencies are still earning strong multiples. The multiple you achieve is driven by defensible EBITDA, compliance readiness, quality metrics, staffing stability, and scale.
1) Market Snapshot: What is Driving Valuations in 2026?
- Deal momentum is returning. Buyers are active again, but diligence is tighter and timelines can stretch when documentation is not ready.
- Quality beats hype. Strong outcomes, clean documentation, and a clear story of defendable earnings win premium pricing.
- Policy and compliance matter more than ever. Owners who can answer diligence fast and clean protect terms and reduce retrades.
2) EBITDA Multiples: The Primary Pricing Lens
Most hospice and home health transactions are priced as a multiple of Adjusted EBITDA. Buyers care about earnings quality, sustainability, and risk. Revenue matters, but it usually matters because it supports EBITDA and scale, not because it is the pricing basis.Highlight: If two agencies have the same revenue but different margins, the higher-margin agency typically commands both a higher dollar value and, often, a higher multiple due to stability and scalability.
3) Hospice EBITDA Multiples (US)
Hospice multiples vary widely based on size, compliance posture, quality reporting readiness, census stability, and referral diversification.Typical multiple bands
- Small independent hospices: ~3x to 6x EBITDA
- Mid-sized regional hospices: ~6x to 10x EBITDA
- Scaled platforms and premium assets: ~10x EBITDA and above (select cases)
Explore hospice resources: Hospice industry page | Hospice valuation and maximizing worth | Market trends and buyer behaviorWhat pushes hospice multiples higher: clean compliance record, stable and documented census economics, strong quality metrics, diversified referrals, and a management team that can operate without owner dependence.
4) Revenue Multiples: How Revenue Ties In (Without Replacing EBITDA)
Revenue multiples are sometimes referenced as shorthand, especially in smaller transactions, early conversations, or asset-style deals. In most healthcare agency transactions, buyers underwrite to adjusted EBITDA and use revenue as a supporting signal of scale, stability, and growth.- Revenue helps explain scale. Larger revenue often means a bigger, more stable operating engine.
- Margins matter. A high-margin agency can appear expensive on revenue but attractive on EBITDA.
- Growth matters. Strong growth with defendable documentation can expand the multiple.
Practical way to think about it: Revenue supports valuation when it translates to repeatable earnings, not when it is inflated by fragile referral concentration, documentation risk, or staffing instability.
5) What Moves Multiples Up or Down in 2026?
Drivers that increase multiples
- Defensible adjusted EBITDA with clear add-backs and clean financial statements
- Compliance readiness and fast answers to diligence questions
- Quality metrics that support the clinical story
- Referral diversification and stable census or admission trends
- Staffing stability with low turnover and strong leadership bench
- Scale and operational consistency across branches
Drivers that reduce multiples
- Unclear add-backs, messy books, missing backup documentation
- Compliance gaps, survey issues, audit exposure, or weak documentation culture
- Overdependence on owner, a single referral source, or a single market relationship
- Chronic staffing shortages that cap growth or threaten continuity
- Inconsistent margins or unstable census economics
Get a Confidential Valuation Conversation
Thinking about selling your hospice agency?
If you want a realistic valuation range and a plan to protect terms, we can walk you through what buyers are paying today and what improves pricing in 2026.
Start with valuation resources | Contact Vallexa for a confidential consultation | Hospice owners
Get Deal Flow and Market Intel
Buying hospice agencies in the US?
Join our buyer network to receive opportunities that match your criteria. We also help buyers benchmark multiples, diligence risk, and move efficiently from LOI to close.
Join Our Buyer Network | View opportunities | Talk to our team
7) FAQ: Hospice Valuation Multiples
What is an EBITDA multiple?
An EBITDA multiple is a common valuation method where a buyer values your agency based on a multiple of adjusted EBITDA. The multiple reflects perceived risk, growth, compliance posture, and scale.What are typical hospice EBITDA multiples in 2026?
Many small independent hospices fall in the ~3x to 6x EBITDA range, while mid-sized regional operations often price in the ~6x to 10x range. Premium platform assets can command higher multiples in select situations.Why do two agencies with similar revenue sell for different prices?
Because earnings, risk, and scalability differ. Buyers pay for defensible cash flow, not just top-line revenue. Margin, documentation quality, referral concentration, and staffing stability can dramatically change value.Do revenue multiples matter in hospice deals?
Revenue multiples may appear in early discussions, but most deals are underwritten on adjusted EBITDA. Revenue matters because it supports scale and earnings, not because it replaces EBITDA as the main pricing basis.How do I increase my multiple before selling?
Improve and document adjusted EBITDA, build a strong diligence package, reduce owner dependency, diversify referrals, and strengthen compliance and quality reporting readiness. Strong presentation and clean documentation protect terms and reduce retrades.How long does it typically take to sell a hospice agency?
Timelines vary. Well-prepared sellers can move faster, while deals can stretch when financials, compliance documentation, or buyer financing slows diligence. Preparing early is a common way to protect value.Can Vallexa reference prior deals without naming names?
Yes. We can reference anonymized outcomes and patterns, such as “Texas home health” or “California hospice,” while keeping seller and buyer identities confidential. More FAQs and guides: Vallexa Advisors main FAQ | Hospice valuation guide | Home health sale processExplore Vallexa Advisors
Want the full picture, including valuation, exit planning, and current opportunities?
Visit VallexaAdvisors.com for seller resources, buyer opportunities, and healthcare M&A insights.
Go to VallexaAdvisors.com | Contact Us | Read the step by step sale guide | Join the buyer network
Disclosure: This report provides general market education and does not constitute legal, tax, or financial advice. Multiples vary widely based on risk, quality, and market conditions.